BAX and neoplasm: reported the in vivo antitumor effects of hellebrigenin [29], and they also indicated that at a dose of 2.5 mg/kg, hellebrigenin reduced tumour weight and induced alterations in the expression of apoptotic proteins, including the upregulation of cleaved caspase‐3, caspase‐9 and Bax and the downregulation of Bcl‐2.